A CRISPR/dCasX‐mediated transcriptional programming system for inhibiting the progression of bladder cancer cells by repressing c‐MYC or activating TP53
Enregistré dans:
Auteurs principaux: | Congcong Cao, Lin Yao, Aolin Li, Quan Zhang, Zhenan Zhang, Xiaofei Wang, Ying Gan, Yuchen Liu, Qian Zhang |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Wiley
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/9664ba87b76a4ed9ba8fa2ebee558d7d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Transcriptome-Wide Map of N6-Methyladenosine Methylome Profiling in Human Bladder Cancer
par: Aolin Li, et autres
Publié: (2021) -
A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.
par: Yann Neuzillet, et autres
Publié: (2012) -
TP53 in Myelodysplastic Syndromes
par: Yan Jiang, et autres
Publié: (2021) -
Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines.
par: Elisabeth Silden, et autres
Publié: (2013) -
CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites
par: Rajeswari Jayavaradhan, et autres
Publié: (2019)